Document Type : Original Article(s)
Authors
- Nazanin Farahbakhsh 1
- Zahra Hooshanginezhad 2
- Shiva Saleh 3
- Fariba Alaei 4
- Fatemeh Azizi 5
- Mohammad Shojaie 6
1 Pediatric Pulmonology Department, Mofid Children’s Hospital, Shahid Beheshti University of medical Sciences, Tehran, Iran
2 Department of Cardiology, Jahrom University of Medical Sciences, Jahrom, Fars, Iran
3 Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Fars, Iran
4 Department of Pediatric Cardiology, Mofid Children’s Hospital, Shahid Beheshti University of medical Sciences, Tehran, Iran
5 Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
6 Cardiology Department, Jahrom University of Medical Sciences. Jahrom, Fars, Iran
Abstract
Background: Coronary Artery Diseases (CAD) are the leading cause of Myocardial Infarction (MI). However, their underlying etiology can be found in the interplay between environmental and genetic factors. On the other hand, it has been shown that Extracellular Matrix (ECM) proteins, such as Thrombospondins (TSP), play a crucial regulatory role in vascular pathologies, including atherogenesis. TSPs are extracellular proteins responsible for intercellular and cell-ECM interactions and are involved in regulating functional responses. Recently, a missense mutation in the TSP-4 gene has been reported to potentially increase the risk of CADs. The present study aimed to investigate the role of rs1866389 Guanosine to Cytosine (G/C) Single Nucleotide Polymorphism (SNP) of the TSP-4 gene on the prevalence of premature MI in southern Iran.
Methods: The present case-control study included 100 patients with premature MI and 100 healthy individuals. The DNA extracted from the blood samples of the participants underwent Polymerase Chain Reaction (PCR) for the sequence of the TSP-4 gene. Afterward, the frequency of C (mutated) and G (normal) alleles of the TSP-4 gene was evaluated in the case and control groups.
Results: According to our findings, there was no significant intergroup difference in gender, age, and smoking status. However, the case group was significantly higher in the prevalence of Diabetes mellitus (DM), Hyperlipidemia (HLP), and Hypertension (HTN) compared to the control group. Moreover, 22%, 49%, and 29% of the case group had CC, GC, and GG genotypes in the TSP-4 gene, respectively, while the prevalence of CC, GC, and GG genotypes were 10%, 44%, and 46% in the control group. Also, the prevalence of allele C was significantly higher in the case group (47%) compared to the control group (33%, P=0.043), showing its significant association with the increased risk of premature MI (OR = 1.80; 95% CI = 1.01-3.19).
Conclusions: The rs1866389 G/C SNP of the TSP-4 gene significantly increased the risk of premature MI in the population of southern Iran. Thus, such mutated gene can be used as a target for gene therapy or a marker for early detection of individuals at high risk for CADs.
Highlights
The google Scholar and PubMed links for Mohammad Shojaie.
Keywords
2. Frangogiannis NG. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015;5(4):1841-75.
3. Dugani SB, Fabbri M, Chamberlain AM, Bielinski SJ, Weston SA, Manemann SM, et al. Premature Myocardial Infarction: A Community Study. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):413-22.
4. Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018;25(4):277-84.
5. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. European Heart Journal. 2017;38(11):774-84.
6. Chaqour B, Karrasch C. Eyeing the Extracellular Matrix in Vascular Development and Microvascular Diseases and Bridging the Divide between Vascular Mechanics and Function. Int J Mol Sci. 2020;21(10).
7. Nielsen SH, Mouton AJ, DeLeon-Pennell KY, Genovese F, Karsdal M, Lindsey ML. Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes. Matrix Biology. 2019;75-76:43-57.
8. Rahman MT, Muppala S, Wu J, Krukovets I, Solovjev D, Verbovetskiy D, et al. Effects of thrombospondin-4 on pro-inflammatory phenotype differentiation and apoptosis in macrophages. Cell Death & Disease. 2020;11(1):53.
9. Wight TN, Kang I, Evanko SP, Harten IA, Chang MY, Pearce OMT, et al. Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation. Frontiers in Immunology. 2020;11.
10. Kirk JA, Cingolani OH. Thrombospondins in the transition from myocardial infarction to heart failure. J Mol Cell Cardiol. 2016;90:102-10.
11. Stenina-Adognravi O, Plow EF. Thrombospondin-4 in tissue remodeling. Matrix Biology. 2019;75-76:300-13.
12. Zhong S, Khalil RA. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. Biochemical Pharmacology. 2019;164:188-204.
13. Wu H, Zhang G, Li Z, Ma J, Han X, Xiang T, et al. Thrombospondin-4 expression as a prognostic marker in hepatocellular carcinoma. Gene. 2019;696:219-24.
14. Palao T, Medzikovic L, Rippe C, Wanga S, Al-Mardini C, van Weert A, et al. Thrombospondin-4 mediates cardiovascular remodelling in angiotensin II-induced hypertension. Cardiovascular Pathology. 2018;35:12-9.
15. Andrés Sastre E, Maly K, Zhu M, Witte-Bouma J, Trompet D, Böhm AM, et al. Spatiotemporal distribution of thrombospondin-4 and -5 in cartilage during endochondral bone formation and repair. Bone. 2021;150:115999.
16. Alehagen U, Shamoun L, Wågsäter D. Increased cardiovascular mortality in females with the a/a genotype of the SNPs rs1478604 and rs2228262 of thrombospondin-1. BMC Medical Genetics. 2020;21(1):179.
17. Butnariu LI, Florea L, Badescu MC, Țarcă E, Costache I-I, Gorduza EV. Etiologic Puzzle of Coronary Artery Disease: How Important Is Genetic Component? Life [Internet]. 2022; 12(6).
18. Forbes T, Pauza AG, Adams JC. In the balance: how do thrombospondins contribute to the cellular pathophysiology of cardiovascular disease? American Journal of Physiology-Cell Physiology. 2021;321(5):C826-C45.
19. Abdelmonem NA, Turky NO, Hashad IM, Abdel Rahman MF, El-Etriby A, Gad MZ. Association of Thrombospondin-1 (N700S) and Thrombospondin-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians. Curr Pharm Biotechnol. 2017;18(13):1078-87.
20. Muppala S, Rahman MT, Krukovets I, Verbovetskiy D, Pluskota E, Fleischman A, et al. The P387 Thrombospondin-4 Variant Promotes Accumulation of Macrophages in Atherosclerotic Lesions. bioRxiv. 2019:666602.
21. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Thrombospondins: A Role in Cardiovascular Disease. Int J Mol Sci. 2017;18(7).
22. Zhou X, Huang J, Chen J, Zhao J, Yang W, Wang X, et al. Thrombospondin-4 A387P polymorphism is not associated with coronary artery disease and myocardial infarction in the Chinese Han population. Clin Sci (Lond). 2004;106(5):495-500.
23. Ferry AV, Anand A, Strachan FE, Mooney L, Stewart SD, Marshall L, et al. Presenting Symptoms in Men and Women Diagnosed With Myocardial Infarction Using Sex‐Specific Criteria. Journal of the American Heart Association. 2019;8(17):e012307.
24. Zierfuss B, Höbaus C, Herz CT, Pesau G, Koppensteiner R, Schernthaner GH. Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes. Heart Vessels. 2020;35(1):52-8.
25. Rincón LM, Sanmartín M, Alonso GL, Rodríguez JA, Muriel A, Casas E, et al. A genetic risk score predicts recurrent events after myocardial infarction in young adults. Revista Española de Cardiología (English Edition). 2020;73(8):623-31.
26. Han Y, Teng X, Liu Z. The role of thrombospondin-4 in cardiovascular diseases. Int J Clin Exp Med. 2020;13(2):358-70.
27. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104(22):2641-4.
28. Wessel J, Topol EJ, Ji M, Meyer J, McCarthy JJ. Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J. 2004;147(5):905-9.
29. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347(24):1916-23.
30. Zhang XJ, Wei CY, Li WB, Zhang LL, Zhou Y, Wang ZH, et al. Association between single nucleotide polymorphisms in thrombospondins genes and coronary artery disease: A meta-analysis. Thromb Res. 2015;136(1):45-51.
)